| Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial JM Liou, CC Chen, MJ Chen, CC Chen, CY Chang, YJ Fang, JY Lee, ... The Lancet 381 (9862), 205-213, 2013 | 339 | 2013 |
| Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial JM Liou, YJ Fang, CC Chen, MJ Bair, CY Chang, YC Lee, MJ Chen, ... The Lancet 388 (10058), 2355-2365, 2016 | 163 | 2016 |
| Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial JM Liou, CC Chen, CY Chang, MJ Chen, YJ Fang, JY Lee, CC Chen, ... Journal of Antimicrobial Chemotherapy 68 (2), 450-456, 2013 | 111 | 2013 |
| Delayed endoscopy as a risk factor for in‐hospital mortality in cirrhotic patients with acute variceal hemorrhage YC Hsu, CS Chung, CH Tseng, TL Lin, JM Liou, MS Wu, FC Hu, HP Wang Journal of gastroenterology and hepatology 24 (7), 1294-1299, 2009 | 108 | 2009 |
| Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis CH Tseng, YC Hsu, TH Chen, F Ji, IS Chen, YN Tsai, H Hai, T Hosaka, ... The Lancet Gastroenterology & Hepatology 5 (12), 1039-1052, 2020 | 106 | 2020 |
| Combining hepatitis B core‐related and surface antigens at end of nucleos (t) ide analogue treatment to predict off‐therapy relapse risk YC Hsu, MH Nguyen, LR Mo, MS Wu, TH Yang, CC Chen, CH Tseng, ... Alimentary Pharmacology & Therapeutics 49 (1), 107-115, 2019 | 99 | 2019 |
| The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors—A … JM Liou, CY Chang, MJ Chen, CC Chen, YJ Fang, JY Lee, JY Wu, JC Luo, ... PLoS One 10 (5), e0124199, 2015 | 94 | 2015 |
| Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial JM Liou, CC Chen, CY Chang, MJ Chen, CC Chen, YJ Fang, JY Lee, ... Gut 65 (11), 1784-1792, 2016 | 85 | 2016 |
| Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos (t) ide analogues for chronic hepatitis B YC Hsu, CY Wu, HY Lane, CY Chang, CM Tai, CH Tseng, GH Lo, ... Journal of Antimicrobial Chemotherapy 69 (7), 1920-1927, 2014 | 59 | 2014 |
| HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort Y Tanaka, E Ogawa, CF Huang, H Toyoda, DW Jun, CH Tseng, YC Hsu, ... Hepatology international 14, 1023-1033, 2020 | 56 | 2020 |
| Inhibition of viral replication reduces transcriptionally active distinct hepatitis B virus integrations with implications on host gene dysregulation YC Hsu, V Suri, MH Nguyen, YT Huang, CY Chen, IW Chang, CH Tseng, ... Gastroenterology 162 (4), 1160-1170. e1, 2022 | 55 | 2022 |
| Endoscopic submucosal dissection for early esophageal neoplasia: a single center experience in South Taiwan CT Lee, CY Chang, CM Tai, WL Wang, CH Tseng, JC Hwang, JT Lin Journal of the Formosan Medical Association 111 (3), 132-139, 2012 | 55 | 2012 |
| Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre … YC Hsu, CY Chen, IW Chang, CY Chang, CY Wu, TY Lee, MS Wu, ... The Lancet Infectious Diseases 21 (6), 823-833, 2021 | 53 | 2021 |
| Long-term outcomes of primary endoscopic resection vs surgery for T1 colorectal cancer: a systematic review and meta-analysis JH Yeh, CH Tseng, RY Huang, CW Lin, CT Lee, PJ Hsiao, TC Wu, LT Kuo, ... Clinical Gastroenterology and Hepatology 18 (12), 2813-2823. e5, 2020 | 49 | 2020 |
| Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of Helicobacter pylori: a randomized trial JM Liou, MJ Bair, CC Chen, YC Lee, MJ Chen, CC Chen, CH Tseng, ... Official journal of the American College of Gastroenterology| ACG 111 (3 …, 2016 | 49 | 2016 |
| Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and … JM Liou, XT Jiang, CC Chen, JC Luo, MJ Bair, PY Chen, CK Chou, ... The Lancet Gastroenterology & Hepatology 8 (3), 228-241, 2023 | 43 | 2023 |
| The benefit of pretreatment esophageal screening with image-enhanced endoscopy on the survival of patients with hypopharyngeal cancer WL Wang, CP Wang, HP Wang, CT Lee, CY Chang, CM Tai, CH Tseng, ... Oral oncology 49 (8), 808-813, 2013 | 40 | 2013 |
| Mac‐2 binding protein glycosylation isomer as a hepatocellular carcinoma marker in patients with chronic hepatitis B or C infection T Jun, YC Hsu, S Ogawa, YT Huang, ML Yeh, CH Tseng, CF Huang, ... Hepatology communications 3 (4), 493-503, 2019 | 37 | 2019 |
| Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium CF Huang, E Iio, DW Jun, E Ogawa, H Toyoda, YC Hsu, H Haga, S Iwane, ... Hepatology international 13, 587-598, 2019 | 35 | 2019 |
| Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B CH Tseng, YC Hsu, CY Chang, TC Tseng, MS Wu, JT Lin, JH Kao Journal of the Formosan Medical Association 117 (10), 915-921, 2018 | 34 | 2018 |
